In cancer, this drug suppresses the PI3K/Akt/mTOR signaling pathway and a previous study evaluated this drug in ACC patients including salivary glands and the best response was SD in 46.7% (7/15) of patients, and no patients had PR or CR (102). Here, AKT1 is linked to adrenal cortex carcinoma.